Artificial Intelligence
BioAge Raises $90M to Treat Aging and Age-related Diseases
Proceeds will support advancement of the company’s pipeline and proprietary platform for identifying and developing therapies to treat diseases of aging
Company announces Chief Medical Officer as it prepares to enter clinic in 2021 with lead Phase 2-ready therapeutic compounds
RICHMOND, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) — BioAge Labs, Inc., a biotechnology company developing medicines to treat aging and aging-related diseases, today announced that it has raised $90 million in an oversubscribed Series C financing. The raise was co-led by Andreessen Horowitz and serial entrepreneur, Elad Gil, and included new investors Kaiser Foundation Hospitals, AARP Foundation (through the RockCreek Impact Fund) and Phi-X Capital, the fund of genomics entrepreneur Mostafa Ronaghi, among others. Current investors including Caffeinated Capital, Redpoint Ventures, PEAR Ventures, AME Cloud Ventures, Felicis Ventures, and others also participated.
“These additional funds will support advancement of our systems biology and data-driven platform to map the key pathways that drive human aging and our pipeline of medicines that target these pathways to reverse or eradicate diseases and extend healthspan,” said Kristen Fortney, PhD, co-founder and chief executive officer. “We look forward to advancing our first platform-derived therapies, BGE-117 and BGE-175 into clinical trials in the first half of 2021.”
“BioAge is at the forefront of understanding scientific drivers of aging with its unique and cutting-edge systems biology platform. We believe their approach has the potential to unlock the underlying pathologies of many diseases, such as Alzheimer’s, cardiovascular disease, and frailty, that disproportionately affect older populations,” said Vijay Pande, PhD, general partner at Andreessen Horowitz.
“Drugs that target aging have potential to treat several morbid diseases and improve the lives of older adults. BioAge has built a proprietary engine to analyze molecular signatures in aging populations, and to advance data-driven hypotheses to identify existing clinical-stage drugs that are ready for Phase 2 efficacy trials in age-related diseases. I’m excited to work with them as they scale their platform and develop multiple therapies to improve the health of older individuals,” said Elad Gil, PhD, entrepreneur and investor.
Proceeds from the financing will be used to build and develop a diversified portfolio of therapies that increase healthspan and lifespan, augment BioAge’s artificial intelligence (AI)-driven approach to map the molecular pathways that impact human longevity, and further expand capabilities to test drug candidates in predictive models of human diseases of aging.
Separately, the company announced that Paul Rubin, M.D. will lead its clinical development efforts as chief medical officer. Dr. Rubin, a veteran biopharmaceutical drug developer, brings extensive experience from early discovery, late stage development and ultimate drug approvals across a wide variety of therapeutic areas in global geographies. In former roles heading development at Sepracor, GSK and Abbott, Dr. Rubin has been responsible for the clinical development and approval of more than ten products. Prior to BioAge, he was most recently executive vice president, Research and Development for MiRagen and held a similar role at Xoma, two biotechnology companies. Dr. Rubin earned his M.D. at Rush Medical College, Chicago.
Dr. Rubin commented, “I am thrilled to be leading the BioAge clinical development team at this exciting time. Our platform provides a unique opportunity to identify targets relevant to the aging process and diseases associated with this process. Diseases common to older patients are often ignored despite their direct association with morbidity, mortality and decreased quality of life. The first two drugs from our pipeline are ready to begin Phase 2 trials in indications targeting serious conditions in elderly populations that presently have no good therapeutic options. A key aspect of our strategy is to initiate efficient human clinical trials that will demonstrate that our drugs can address age-related deficiencies in acute conditions, which may expedite approval and serve as a gateway to the treatment of chronic diseases, resulting in healthy aging.”
About the BioAge Platform
The BioAge platform identifies key drug targets that will impact aging. The company’s proprietary human aging cohorts have blood samples collected up to 45 years ago, with participant -omics data that is tied to extensive medical follow-up records including detailed future healthspan, lifespan and disease outcomes. BioAge has built a systems biology and AI platform that leverages these rich datasets to identify the molecular drivers of age-related pathology. BioAge’s pipeline of therapies targeting these key pathways will address the significant unmet medical needs of an aging population.
About BioAge
BioAge is a privately-held biotechnology company developing proprietary drugs to treat aging and aging- related diseases. Since its founding in 2015, the Company has raised $127 million in venture capital funding to back its AI-driven approach to map the molecular pathways that impact human longevity. BioAge’s mission is to develop a pipeline of therapeutic assets that increase healthspan and lifespan. For additional information about BioAge, visit the company’s website at www.bioagelabs.com.
Source: BioAge Labs, Inc.
Contact Information:
BioAge | [email protected]
Media | [email protected]
Artificial Intelligence
Aetina Accelerates Embedded AI with High-performance, Small Form-factor Aetina IA380E-QUFL Graphics Card
TAIPEI, April 25, 2024 /PRNewswire/ — Aetina, a leading Edge AI solution provider, announced the launch of the Aetina IA380E-QUFL at Embedded World 2024 in Nuremberg, Germany. This groundbreaking product is a small form factor PCIe graphics card powered by the high-performance Intel Arc A380E GPU.
Unmatched Power in a Compact Design
The Aetina IA380E-QUFL delivers workstation-level performance packed into a low-profile, single-slot form factor. This innovative solution consumes only 50W, making it ideal for space and power-constrained edge computing environments. Embedded system manufacturers and integrators can leverage the power of 4.096 TFLOPs peak FP32 performance delivered by the Intel Arc A380E GPU[1].
Beyond Small Size: Big Capabilities
Despite its compact size, the IA380E-QUFL offers native support for 4 mini-DisplayPort outputs and 6GB of GDDR6 memory, enabling the connection of multiple high-resolution displays (UHD). This makes the IA380E-QUFL an excellent choice for a wide range of applications, including commercial gaming, video walls, medical imaging, and visual inference for smart cities.
“The demand for slim and energy-efficient AI systems is rapidly escalating,” said Jackal Chen, Senior Product Manager at Aetina. “The Aetina IA380E-QUFL addresses this need head-on, offering a powerful GPU solution in a compact, single-slot form factor with minimal power consumption. This empowers developers to create powerful and efficient edge systems for a wide range of applications.”.
Unparalleled Commitment: 5-Year Product Supply
Acknowledging the critical need for long-term product stability in industrial applications, Aetina ensures a 5-year product supply for the Aetina IA380E-QUFL, which streamlines system roadmaps and reduces the need for costly redesign. Our commitment is aligned with Intel’s announced product plans for the Intel Arc A380E GPU.[1]
[1]https://www.intel.com/content/www/us/en/content-details/820389/intel-arc-gpu-for-the-edge-public-30-3-30.html?wapkw=Intel%20Arc%20GPU%2030-3-30&DocID=820389 Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
Photo – https://mma.prnewswire.com/media/2395995/High_performance_Small_Form_factor_Aetina_IA380E_QUFL_Graphics_Card.jpg
View original content:https://www.prnewswire.co.uk/news-releases/aetina-accelerates-embedded-ai-with-high-performance-small-form-factor-aetina-ia380e-qufl-graphics-card-302125786.html
Artificial Intelligence
IG Canada Announces Enhanced Trading Platform for Enhanced User Experience
Meta description : Explore IG Canada’s advanced trading platform, educational resources, and robust security features. Achieve your trading goals with the innovative tools.
NOTTINGHAM, England, April 25, 2024 /PRNewswire/ — IG Canada, a premier online trading platform, is pleased to announce significant enhancements to its trading technology, designed to empower both novice and experienced traders with superior tools and resources. This development is part of IG Canada’s commitment to providing the best trading experience in the Canadian market.
IG Canada has upgraded its platform with advanced features that streamline trading processes and improve the accuracy of trade execution. These enhancements include customizable charts, a wider range of indicators, and improved mobile access, ensuring traders can operate efficiently from anywhere at any time.
Recognizing the importance of education in trading success, IG Canada has expanded its educational resources. The brokerage now offers a comprehensive learning center featuring webinars, tutorials, and articles that cater to various skill levels. These resources are designed to help traders develop robust trading strategies and improve their market knowledge.
Security remains a top priority for IG Canada. The latest updates include enhanced encryption and multi-factor authentication to protect client data and funds. These security measures provide peace of mind for traders, knowing their investments are safeguarded against potential threats.
IG Canada is a leading online brokerage that provides trading services across multiple asset classes, including forex, stocks, commodities, and indices. With a focus on innovation and customer service, IG Canada is committed to helping Canadian traders achieve their investment goals through a transparent and efficient trading environment.
In addition, IG Canada is committed to engaging with the community through upcoming webinars, live events, and partnerships with local financial experts. These initiatives are designed not only to support the growth and education of the clients but also to foster a stronger, more connected trading community in Canada.
Press Contact:Contact Name: Timothy C. SherwinEmail: [email protected] Phone: +447 441425053
View original content:https://www.prnewswire.co.uk/news-releases/ig-canada-announces-enhanced-trading-platform-for-enhanced-user-experience-302127189.html
Artificial Intelligence
Sentrycs Now Part of the UK National Protective Security Authority Catalog of Security Equipment
This inclusion into the NPSA CSE marks a significant milestone in the company’s commitment to enhancing national and international airspace security and to leading the C-UAS market toward multi-layer strategy optimization and excellence.
TEL-AVIV, Israel, April 25, 2024 /PRNewswire/ — Sentrycs, a leading innovator in adaptive counter-drone solutions, is proud to announce its inclusion in the prestigious UK National Protective Security Authority Catalogue of Security Equipment (NPSA CSE).
Following a rigorous assessment process, Sentrycs’ cutting-edge Counter Unmanned Aerial Systems (C-UAS) solution has met the high standards set by the NPSA for Detection, Tracking, and Identification (DTI). The testing, conducted at the NPSA’s designated testing facilities in August 2023, rigorously evaluated the Sentrycs system against the NPSA’s DTI Testing and Evaluation Standard v3.1.
Sentrycs elected to be assessed under Configuration D as a 3D system with Ground Control Station (GCS) detection capability and platform identification capability, which is the most demanding test scenario with the highest number of scored parameters.
The Sentrycs system demonstrated exceptional capabilities in various security scenarios, showcasing its robustness in detecting and tracking with high accuracy and zero false alarms. The system’s innovative use of cyber techniques to extract data from targets and its streamlined human-machine interface were especially noted for their efficiency and ease of use.
“Our team is proud to have Sentrycs recognized by the UK National Protective Security Authority,” said Yoav Zaltzman, CEO of Sentrycs. “Being listed in the CSE is not just an honor; it’s a testament to our technology’s reliability and effectiveness in contributing to the ever-changing airspace security landscape.”
Sentrycs’ technology is now accessible through the NPSA CSE, providing security practitioners with verified solutions that meet the UK’s rigorous security standards. This inclusion not only underscores Sentrycs’ role in advancing security technology but also enhances its visibility and credibility on a global stage.
For more details on Sentrycs’ solutions and their impact, visit www.sentrycs.com.
For further information regarding the NPSA and the Catalog of Security Equipment, please visit the NPSA’s official website.
About Sentrycs
Sentrycs is a leader in adaptive counter-drone solutions, supported by innovative technology designed to passively identify, mitigate, and where necessary, intercept unauthorized drones custom-built for various environments – including airports, borders, prisons, critical infrastructure, and mass events. Founded in 2017, Sentrycs’ has offices in Israel and the US, serving customers worldwide. By uniting its field-proven technology and expertise in global drone environments, Sentrycs is leading the way towards a safer and more secure drone-driven future. Learn more at www.sentrycs.com
Video – https://www.youtube.com/watch?v=YBuhpTq5QuM
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/sentrycs-now-part-of-the-uk-national-protective-security-authority-catalog-of-security-equipment-302126952.html
-
Uncategorized6 days ago
Generative AI gold rush drives IT spending — with payoff in question
-
Uncategorized6 days ago
Do underwriters trust artificial intelligence?
-
Uncategorized6 days ago
Hans Jonas on Responsibility in the Age of Artificial Intelligence
-
Uncategorized6 days ago
Meta AI Assistant Adds Website, Expands Beyond US
-
Artificial Intelligence6 days ago
Free Your Hands, QIDI Vida Smart AR Glasses Lead the Way in New Sports Experience.
-
Uncategorized6 days ago
Can artificial intelligence reduce vehicle time to market?
-
Uncategorized6 days ago
The Ottawa Hospital doctors to try AI for patient notes
-
Artificial Intelligence5 days ago
Aurionpro Solutions acquires Arya.ai, to power next generation Enterprise AI platforms for Financial Institutions